Literature DB >> 19800061

Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles.

Johnny S Younis1, Sofia Soltsman, Ido Izhaki, Orit Radin, Shalom Bar-Ami, Moshe Ben-Ami.   

Abstract

OBJECTIVE: To investigate whether early and short follicular administration of GnRH antagonist using the flexible protocol has the potential to improve IVF-ET clinical results.
DESIGN: Prospective, controlled, randomized study.
SETTING: University-affiliated assisted reproductive technology unit. PATIENT(S): Fifty-three consecutive infertile women were enrolled to the study and control groups. INTERVENTION(S): Both groups were treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group were additionally supplemented with three injections of GnRH antagonist (0.25 mg/d on days 1, 2, and 3 of the menstrual cycle). MAIN OUTCOME MEASURE(S): Hormonal milieu, oocyte meiotic status, competence for normal fertilization, cleavage, and clinical pregnancy rate. RESULT(S): Both groups had comparable baseline characteristics. The duration of recombinant FSH treatment was significantly longer in the study group as compared with the control group (10.9+/-3.1 and 9.7+/-1.3 days, respectively). The number of follicles>or=14 mm and E2 level on the day of hCG administration, number of retrieved oocytes, and endometrial thickness were similar between the two groups. However, the fertilization rate was significantly higher in the study as compared with the control group (85%+/-16% and 69%+/-24%, respectively). Moreover, the cumulative rate of mature first polar body oocytes was significantly higher in the study group as compared with the control group (93% and 85%, respectively). Concomitantly, day-3 FSH and LH levels after initiation of treatment were significantly lower in the study as compared with the control group (6.1+/-2.4 mIU/mL vs. 7.2+/-1.9 mIU/mL and 2.4+/-1.6 mIU/mL vs. 5.6+/-2.7 mIU/mL, respectively). CONCLUSION(S): Early and short follicular GnRH antagonist supplementation using flexible GnRH antagonist treatment improves the meiotic status and competence of retrieved oocytes. It seems that early and short pituitary shutdown has the potential to improve clinical results in IVF-ET GnRH antagonist cycles. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800061     DOI: 10.1016/j.fertnstert.2009.08.033

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

Review 1.  Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy--clinical approach and unsolved issues.

Authors:  Katharina Hancke; Vladimir Isachenko; Evgenia Isachenko; Jürgen M Weiss
Journal:  Support Care Cancer       Date:  2011-09-23       Impact factor: 3.603

2.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.

Authors:  Hakan Cakmak; Nam D Tran; A Musa Zamah; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

Review 3.  Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis.

Authors:  Shuang Yang; Nenghui Liu; Yanping Li; Lei Zhang; Rongya Yue
Journal:  Arch Gynecol Obstet       Date:  2020-11-24       Impact factor: 2.344

4.  Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol.

Authors:  Chan Woo Park; Yu Im Hwang; Hwa Seon Koo; Inn Soo Kang; Kwang Moon Yang; In Ok Song
Journal:  Clin Exp Reprod Med       Date:  2014-12-31

Review 5.  Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials.

Authors:  Man Di; Xiaohong Wang; Jing Wu; Hongya Yang
Journal:  Arch Gynecol Obstet       Date:  2022-06-11       Impact factor: 2.344

6.  Delayed Start Protocol with Gonadotropin-releasing Hormone Antagonist in Poor Responders Undergoing In Vitro Fertilization: A Randomized, Double-blinded, Clinical Trial.

Authors:  Afsoon Zarei; Mohammad Ebrahim Parsanezhad; Maryam Azizi Kutenaei; Bahia Namavar Jahromi; Parastoo Soheil Esfahani; Pardis Bakhshaei
Journal:  Oman Med J       Date:  2018-11

7.  Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT.

Authors:  Robab Davar; Nosrat Neghab; Elham Naghshineh
Journal:  Int J Reprod Biomed       Date:  2018-04

8.  Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.

Authors:  Yisheng Zhang; Liling Liu; Jie Qin; Hongyi Huang; Lintao Xue; Shikai Wang; Weihong Tan
Journal:  Reprod Biol Endocrinol       Date:  2021-10-12       Impact factor: 5.211

9.  Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization.

Authors:  Hwajeong Lee; Hyun Joung Choi; Kwang Moon Yang; Min Jung Kim; Sun Hwa Cha; Hyun Jeong Yi
Journal:  Obstet Gynecol Sci       Date:  2017-12-19

10.  Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial.

Authors:  Maryam Eftekhar; Ramesh Baradaran Bagheri; Nosrat Neghab; Robabe Hosseinisadat
Journal:  JBRA Assist Reprod       Date:  2018-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.